41.70MMarket Cap-638P/E (TTM)
1.020High0.995Low61.58KVolume1.020Open1.040Pre Close62.17KTurnover0.30%Turnover RatioLossP/E (Static)41.09MShares1.76052wk High0.36P/B21.15MFloat Cap0.63052wk Low--Dividend TTM20.83MShs Float18.948Historical High--Div YieldTTM2.40%Amplitude0.630Historical Low1.009Avg Price1Lot Size
Achilles Therapeutics Stock Forum
Achilles Therapeutics Discontinued Its TIL-Based CNeT Program And Closed Phase 1/2A CHIRON and THETIS Trials, And It Will Refocus Its Strategy To Explore Further Engagement With Third Parties, The Company Has Engaged BofA Securities To Provide Strategic Financial Advice
NEWS
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Moomoo 24/7· 1 min ago
Achilles Therapeutics (ACHL.Improved VELOS manufacturing process delivering higher cNeT doses.
Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024.
First three patients dosed in CHIRON and T...
Watchlist.
$ZyVersa Therapeutics (ZVSA.US)$ $Roma Green Finance (ROMA.US)$ $Veru Inc (VERU.US)$ $Achilles Therapeutics (ACHL.US)$ $Gaxos.ai (GXAI.US)$ $Applied Therapeutics (APLT.US)$ $Sonder Holdings (SOND.US)$
📊⚡️📊
No comment yet